Company profile
Nanolynx Biologics
Conditionally Active Nanobody-Drug Conjugates for Hard-to-Treat Solid Tumors
- Industry
- Biotechnology Research
- Employees
- 3
- Headquarters
- Allschwil
- Founded
- 2025
- Office locations
- 1
Nanolynx Biologics company summary
Nanolynx Biologics is a company in the Biotechnology Research industry, headquartered in Allschwil, founded in 2025. On LinkedIn the company has around 3 employees.
What technology does Nanolynx Biologics use?
No technologies detected yet. Warmrank rechecks company websites on a rolling basis.
About Nanolynx Biologics
Nanolynx is developing conditionally active nanobody-drug conjugates (CA-NDCs), a new class of targeted cancer medicines designed to overcome key limitations of conventional antibody-drug conjugates (ADCs). Our IntelliBody™ platform combines tumor-selective activation with the superior tissue penetration of nanobodies to expand the therapeutic window and unlock challenging cancer targets constrained by toxicity and limited tumor accessibility. Powered by one of the world's largest nanobody datasets, we are building the next generation of targeted therapies for patients with hard-to-treat solid tumors.
Where is Nanolynx Biologics located?
Nanolynx Biologics lists 1 location.
Compare companies similar to Nanolynx Biologics
More companies in Biotechnology Research.
| Company | Industry | Employees | Founded | Headquarters |
|---|---|---|---|---|
Nanolynx Biologics nanolynx.bio | Biotechnology Research | 3 | 2025 | Allschwil |
 Thermo Fisher Scientific thermofisher.com | Biotechnology Research | 100,779 | - | Waltham, MA |
 Amgen amgen.com | Biotechnology Research | 41,028 | 1980 | Thousand Oaks, CA |
 Biogen biogen.com | Biotechnology Research | 7,742 | - | Cambridge, MA |
 Biocon biocon.com | Biotechnology Research | 11,902 | - | Bangalore, Karnataka |
| Biotechnology Research | 28,679 | - | Bethesda, MD | |
 Genentech gene.com | Biotechnology Research | 18,296 | 1976 | South San Francisco, California |
 Eurofins eurofins.com | Biotechnology Research | 24,928 | - | Luxembourg, Luxembourg |
 Gilead Sciences gilead.com | Biotechnology Research | 14,743 | - | Foster City, CA |
 Syneos Health syneoshealth.com | Biotechnology Research | 23,772 | - | Morrisville, NC |
 Moderna modernatx.com | Biotechnology Research | 6,238 | 2010 | Cambridge, Massachusetts |
Frequently asked questions about Nanolynx Biologics
What does Nanolynx Biologics do?
Nanolynx is developing conditionally active nanobody-drug conjugates (CA-NDCs), a new class of targeted cancer medicines designed to overcome key limitations of conventional antibody-drug conjugates (ADCs). Our IntelliBody™ platform combines tumor-selective activation with the superior tissue penetration of nanobodies to expand the therapeutic window and unlock challenging cancer targets constrained by toxicity and limited tumor accessibility. Powered by one of the world's largest nanobody datasets, we are building the next generation of targeted therapies for patients with hard-to-treat solid tumors.
How many employees does Nanolynx Biologics have?
Nanolynx Biologics has around 3 employees on LinkedIn.
Where is Nanolynx Biologics headquartered?
Nanolynx Biologics is headquartered in Allschwil.
When was Nanolynx Biologics founded?
Nanolynx Biologics was founded in 2025.
Build a lead list from companies like Nanolynx Biologics
Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.